Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-7762. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 18/20 | 1.00 |
| ▸ | MELK | Q14680 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-7762 SCHEMBL1564574 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL31517325 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL15105420 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL29388936 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL29994838 | 0.99 | MELK (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL19457662 | 0.99 | MELK (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| SCHEMBL31532638 | 0.97 | CHEK1 (0.95) | CHEK1MELKPLK4GAKJAK2 | |
| SCHEMBL31532541 | 0.97 | CHEK1 (0.95) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL1127337 | 0.96 | CHEK1 (0.92) | CHEK1MELKPLK4GAKJAK2 | |
| SCHEMBL31532639 | 0.94 | CHEK1 (0.89) | CHEK1MELKPLK4GAKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| EP-3947736-B1 | PROGNOSIS METHOD OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2026-03-11 | — | — | EP | claimed |
| US-20260053775-A1 | METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S) | UNIV COLUMBIA (US) | 2026-02-26 | — | — | US | claimed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20250387643-A1 | METHODS AND APPARATUS FOR APPLYING TUMOR TREATING FIELDS COMBINED WITH PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-12-25 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| US-12491176-B2 | Methods, compositions, kits and uses thereof targeting and/or treating VRK2 to enhance effectiveness of immune checkpoint inhibitor(s) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-12-09 | — | — | US | claimed |
| US-20250326859-A1 | ANTI-CANCER ANTIBODIES, COMBINATION THERAPIES, AND USES THEREOF | PREC BIOLOGICS INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | claimed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | claimed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | claimed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-20160252530-A1 | AGENT FOR PREVENTING OR TREATING SPINOCEREBELLAR ATAXIA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2016-09-01 | — | — | US | claimed |
| EP-3056210-A1 | DRUG FOR PREVENTION OR TREATMENT OF SPINOCEREBELLAR DEGENERATION | National University Corporation Tokyo Medical and Dental University (JP) | 2016-08-17 | — | — | EP | claimed |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-10 | — | — | US | claimed |
| WO-2012162584-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | claimed |
| EP-2305671-A1 | Thiophene and thiazole derivatives as CHK1 inhibitors | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| EP-1732920-B1 | THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | CHEK1 67/4885MELK 1416/4885PLK4 205/4885 |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CHEK1 21/4885MELK 117/4885PLK4 15/4885 |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | CHEK1 178/4885MELK 1019/4885PLK4 182/4885 |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CHEK1 21/4885MELK 117/4885PLK4 15/4885 |
| US-12491176-B2 | Methods, compositions, kits and uses thereof targeting and/or treating VRK2 to enhance effectiveness of immune checkpoint inhibitor(s) | VRK2, VRK1, PDCD1LG2 | CHEK1 9/4885MELK 315/4885PLK4 149/4885 |
| US-20260053775-A1 | METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S) | VRK2, VRK1, PDCD1 | CHEK1 8/4885MELK 308/4885PLK4 82/4885 |
| US-20250387643-A1 | METHODS AND APPARATUS FOR APPLYING TUMOR TREATING FIELDS COMBINED WITH PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY | IFNAR1, IFNG, PDCD1 | CHEK1 119/4885MELK 3766/4885PLK4 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.